Biomerica Inc. (BMRA)
undefined
undefined%
At close: undefined
0.32
-6.97%
After-hours Jan 03, 2025, 05:52 PM EST

Company Description

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide.

The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.

It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories.

The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection.

Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Biomerica Inc.
Biomerica Inc. logo
Country United States
IPO Date Sep 7, 1984
Industry Medical - Devices
Sector Healthcare
Employees 64
CEO Zackary S. Irani

Contact Details

Address:
17571 Von Karman Avenue
Irvine, California
United States
Website https://www.biomerica.com

Stock Details

Ticker Symbol BMRA
Exchange NASDAQ
Fiscal Year June - May
Reporting Currency USD
CIK Code 0000073290
CUSIP Number 09061H307
ISIN Number US09061H3075
Employer ID 95-2645573
SIC Code 2835

Key Executives

Name Position
Zackary S. Irani Chief Executive Officer & Director
Gary Lu CPA Principal Accounting Officer & Chief Financial Officer
Allen C. Barbieri Executive Vice-Chairman of the Board & Corporate Secretary
Lucy Liu Ph.D. Director of Manufacturing & Technical Operations

Latest SEC Filings

Date Type Title
Dec 20, 2024 S-8 Filing
Dec 17, 2024 4 Filing
Dec 17, 2024 4 Filing
Dec 17, 2024 4 Filing
Dec 17, 2024 4 Filing
Dec 17, 2024 4 Filing
Dec 17, 2024 4 Filing
Dec 17, 2024 8-K Current Report
Nov 25, 2024 S-8 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...